产品
编 号：F336912
分子式：C14H11NO2S
分子量：257.31
分子式：C14H11NO2S
分子量：257.31
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 36341-25-0
产品详情
生物活性：
YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness.
体内研究：
YL-109 (15 mg/kg; s.c. for every 2 d) inhibits both tumor growth and cancer metastasis of breast cancer cells in vivo.Animal Model:BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells
Dosage:15 mg/kg
Administration:S.c. every 2 days for 63 days
Result:Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells.
体外研究：
YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell proliferation, motility, and invasiveness in breast cancer cells.YL-109 (1 μM) increases both CHIP mRNA and protein levels in MDA-MB-231 cells.
YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness.
体内研究：
YL-109 (15 mg/kg; s.c. for every 2 d) inhibits both tumor growth and cancer metastasis of breast cancer cells in vivo.Animal Model:BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells
Dosage:15 mg/kg
Administration:S.c. every 2 days for 63 days
Result:Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells.
体外研究：
YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell proliferation, motility, and invasiveness in breast cancer cells.YL-109 (1 μM) increases both CHIP mRNA and protein levels in MDA-MB-231 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备